Breadth and function of antibody response to acute SARS-CoV-2 infection in humans

• DOI: 10.1371/journal.ppat.1009352
• Publication Date: 2021-02-26T18:45:43Z
• Authors: Kuan-Ying A. Huang; Tiong Kit Tan; Ting-Hua Chen; Chung-Guei Huang; Ruth Harvey; Saira Hussain; Cheng-Pin Chen; Adam Harding; Javier Gilbert-Ja...; Xu Liu; Michael Knight; Lisa Schimanski; Shin-Ru Shih; Yi-Chun Lin; Chien-Yu Cheng; Shu-Hsing Cheng; Yhu-Chering Huang; Tzou-Yien Lin; Jia-Tsrong Jan; Che Ma; William James; Rodney S. Daniels; John W. McCauley; Pramila Rijal; Alain R. Townsend
• Keywords: Adult; Binding Sites; QH301-705.5; SARS-CoV-2; Antibodies, Monoclonal; COVID-19; RC581-607; Antibodies, Viral; Antibodies, Neutralizing; 3. Good health; Epitopes; Immunoglobulin G; Spike Glycoprotein, Coronavirus; Humans; Angiotensin-Converting Enzyme 2; Immunologic diseases. Allergy; Biology (General); Antibody-Producing Cells; Nucleocapsid; Research Article

Serological and plasmablast responses plasmablast-derived IgG monoclonal antibodies (MAbs) have been analysed in three COVID-19 patients with different clinical severities. Potent humoral were detected within 3 weeks of onset illness all the serological titre was elicited soon after or concomitantly peripheral response. An average 13.7% 3.5% MAbs reactive virus spike glycoprotein nucleocapsid, respectively. A subset anti-spike (10 32) cross-reacted other betacoronaviruses tested harboured extensive somatic mutations, indicative an expansion memory B cells upon SARS-CoV-2 infection. Fourteen 32 MAbs, including five anti-receptor-binding domain (RBD), anti-non-RBD S1 six anti-S2, neutralised wild-type independent assays. Anti-RBD further grouped into four cross-inhibiting clusters, which from separate clusters blocked binding RBD to ACE2 neutralising. All ACE2-blocking anti-RBD isolated two recovered prolonged fever, is compatible substantial response their sera. Finally, identification non-competing pairs neutralising would offer potential templates for development prophylactic therapeutic agents against SARS-CoV-2.